Business Wire

ICR Acquires Consilium Strategic Communications, Creating Global Leader in Healthcare Communications and Investor Relations

12.9.2023 14:50:00 EEST | Business Wire | Press release

Share

ICR, a leading global strategic communications and advisory firm, today announced it has acquired Consilium Strategic Communications, a leading international strategic healthcare communications and investor relations firm focused on Europe and headquartered in London. The transaction, which follows almost a decade of joint venture collaboration, will combine Consilium with ICR’s US-based healthcare practice, ICR Westwicke, forming a global healthcare strategic and financial communications powerhouse with nearly 200 clients and more than 100 team members across three continents.

Current clients of Consilium will immediately benefit from the full breadth of ICR’s services including: investor relations; capital markets and IPO advisory; investor access; ESG advisory; corporate communications and media relations; crisis and special situations; marketing PR; social media; and branding & design. Consilium will operate under the “ICR Consilium” brand and integrate its teams and activities with ICR’s existing healthcare practice.

Consilium was formed in 2013 by Mary-Jane Elliott, Founder and Managing Partner, along with Amber Fennell, Senior Partner and Co-founder. Over the past 10 years the firm has grown to become the market leader in healthcare strategic communications and IR in Europe. Mary-Jane Elliott will continue to lead the firm from its headquarters in London and both she and Amber Fennell will join the ICR healthcare leadership team, which includes Mark Klausner and Bob East (for Investor Relations), and Terri Clevenger and Michael O’Brien (for Public Relations). The transaction establishes ICR’s first official on-the-ground presence in Europe, broadening its global footprint to now include North America, Asia Pacific and UK/Europe.

Tom Ryan, Founder & CEO of ICR, said: “Consilium has long been recognized as the preeminent healthcare communications and advisory firm across Europe and our years of collaboration have allowed us to learn first-hand what makes them so unique. MJ, Amber and their team have built an incredible business, with a hard-earned reputation for deep sector expertise, highly strategic counsel and outstanding client service. Their business and culture could not align more perfectly with ICR’s and we are thrilled to advance our partnership as a single, unified team.

“We were fortunate to add the Westwicke team to ICR in 2019 and have enjoyed tremendous success since then, growing our healthcare practice nearly three-fold. Combining the Consilium and ICR Westwicke teams allows us to offer truly comprehensive global support to healthcare companies while also extending ICR’s presence into Europe,” Mr. Ryan continued.

Mary-Jane Elliott, Managing Partner at ICR Consilium, said: "Over the past 10 years we have had the great pleasure to build Consilium into Europe's leading independent strategic communications agency for the healthcare sector with the sole purpose of serving our clients globally. I am extremely proud of what we have achieved as a team and thank our clients, colleagues past and present, and fellow advisors for their ongoing trust and support.

"I am excited by our next phase of growth as part of ICR, who are backed by two leading global private equity firms – CDPQ and Investcorp, and what opportunities this offers, particularly in the US, to our clients and colleagues, including offering a broader range of capabilities. We have been joint-venture partners for almost a decade and have a complementary fit in international healthcare PR and IR advisory work. Over the years of working with ICR we have shared many clients and delivered fantastic and seamless benefits, as well as formed strong relationships with the ICR team across the US. Now is the right time to deepen that relationship, which coincides with hopefully the continued re-opening of the capital markets, and we look forward to what we can accomplish together,” Mary-Jane Elliott added.

This transaction creates one of the largest global specialist healthcare communications practices and significantly enhances ICR’s capabilities in Europe, by increasing its practice size in both revenue and headcount and broadening its service offerings. The ICR and Consilium combination will immediately provide existing and new ICR Consilium clients with access to integrated support across ICR’s entire platform of services and the combination creates exciting new growth opportunities for all team members.

Together, ICR and Consilium bring unmatched depth of expertise in healthcare advisory services across IR and strategic communications and the capabilities to support healthcare companies globally across all subsectors including biopharma, medical technology, diagnostics, healthcare services and information technology, and through all stages of growth from early-stage development, to public offerings, to mature public companies. The firm’s full range of critical strategic communication and investor relations services enable the combined team to support healthcare businesses and leaders with strategic expertise for gaining investor support, building and managing reputation, executing and communicating capital raising and other transactions, responding to crises, introducing new products, communicating regulatory developments and more.

Consilium's team of more than 45 PR and IR professionals, including former journalists, sell-side analysts, industry communications experts, and financial PR practitioners combines with ICR Westwicke’s more than 70 team members with similar professional backgrounds in healthcare. Consilium adds to ICR’s existing client base and bolsters the firm’s expertise in strategic healthcare communications and investor relations, with deep industry knowledge and an unrivalled network across the US, UK, continental Europe and Asia.

Amber Fennell, Senior Partner, ICR Consilium, added: “The combination of Consilium with ICR creates an unrivalled transatlantic strategic communications practice providing support across all aspects of healthcare corporate communications and financial transactions. ICR has an excellent brand and reputation and is one of the fastest growing communications agencies in the US. Working together we will be able to provide our combined healthcare clients with even more seamless and integrated access to a breadth of PR and IR advisory services, in London, across Europe and in the US.”

Notes to editors

About ICR

Established in 1998, ICR partners with its clients to execute strategic communications and advisory programs that achieve business goals, build awareness and credibility, and enhance long-term enterprise value. The firm’s highly-differentiated service model, which pairs capital markets veterans with senior communications professionals, brings deep sector knowledge and relationships to approximately 1,000 clients across more than 20 industry groups. ICR’s healthcare practice operates under the ICR Westwicke brand (www.westwicke.com). Today, ICR is one of the largest and most experienced independent communications and advisory firms in North America, maintaining offices in New York, Norwalk, Boston, Baltimore, San Diego, San Jose and Beijing. Learn more at www.icrinc.com. Follow us on Twitter at @ICRPR and LinkedIn.

About ICR Consilium

ICR Consilium is a global leader in financial and corporate communications and investor relations focused on the healthcare sector. ICR Consilium's team, based in Europe and the US, provides strategic, long-term PR and IR advice to healthcare companies, Boards, senior decision-makers and executives on critical communications programs, international media management, transactions and healthcare stakeholder challenges. ICR Consilium has established deep knowledge and expertise across all areas of the global healthcare sector through broad involvement in representing international clients spanning the Fortune 500, FTSE 100, FTSEurofirst 300 and FTSE 250, through to discrete specialist reputation management projects.

For more information, please see www.consilium-comms.com

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

For more information:
ICR
Matt Lindberg
Tel: +1(203) 644-7028
Matthew.Linberg@icrinc.com

ICR Consilium
Mary-Jane Elliott / Amber Fennell
Tel: +44(0)20 3709 5700
info@consilium-comms.com
www.consilium-comms.com
Follow us: @consiliumhc

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

CorFlow Therapeutics Announces Successful Completion of Phase 1 and First Patients Enrolled in Phase 2 of the MOCA II Pivotal Trial, Approval to Start the REVITALISE RCT in Europe, and Strengthening of Clinical Leadership30.4.2026 14:00:00 EEST | Press release

CorFlow Therapeutics AG (CorFlow), a clinical-stage company focused on transforming the diagnosis and treatment for heart attack patients, today announced multiple milestones in advancing its clinical program and the strengthening of clinical leadership. Phase 1 of the company’s MOCA II FDA Pivotal Trial was successfully reached after safety and performance goals were met with STEMI heart attack patients who had the proprietary PCoFI diagnostic measurement of microvascular obstruction (MVO) made during a stenting procedure, when compared to the reference standard diagnosis by cardiac MRI in the subsequent days. Phase 1 included 19 patients enrolled across 5 US and 3 European sites. MOCA II follows the FIH MOCA I study and primarily aims to validate the threshold value of the proprietary PCoFI measurement for diagnosing MVO in the setting of primary angioplasty compared to cardiac MRI. This milestone achievement, which was confirmed by the study’s independent DSMB (Data and Safety Monit

Agendia to Present New Data Demonstrating the Expanded Clinical Utility of MammaPrint ® and BluePrint ® at the 2026 ESMO Breast Cancer Annual Congress30.4.2026 14:00:00 EEST | Press release

Agendia®, Inc., a leader in precision oncology for breast cancer, today announced it will present new data at the 2026 European Society for Medical Oncology (ESMO) Annual Congress on Breast Cancer, taking place May 6-8 in Berlin, Germany. The company will present two posters featuring data from the prospective FLEX Study and an independent post hoc analysis of the landmark MINDACT trial that underscore the prognostic value of MammaPrint® + BluePrint® in early-stage breast cancer (EBC). Poster #65P | Thursday, May 7, 13:15 – 14:15 p.m. CEST | Presenter: Elena Shagisultanova Prognostic Performance of MammaPrint in Patients with Small T1a, b, and c Node-Negative Early Breast Cancer A retrospective analysis from the FLEX Study involving 4,349 patients highlights the biological heterogeneity within small, node-negative (T1a, b, and c) tumors – a group that typically has favorable outcomes. MammaPrint (MP) identified a High Risk 2 (H2) subset, representing 10% of all patients and 5% of those

The Biggest Predictor of Business Growth Is Behavior30.4.2026 10:00:00 EEST | Press release

IDEO, the global design and innovation company, today announced the IDEO Innovation Quotient (IDEO IQ), a new report measuring how workplace behaviors drive business performance across 100 of the world’s largest companies. Those with the highest IDEO IQ scores earned nearly $20 billion in profit last year—50% higher than average and three times more than those ranked at the bottom. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429978890/en/ The IDEO Innovation Quotient (IDEO IQ) is a new report measuring how workplace behaviors drive business performance across 100 of the world’s largest companies. The IDEO IQ surveyed 266 leaders in product and innovation roles at 100 of the world’s largest companies across the Media & Technology, Healthcare, and Consumer Goods sectors. The report is the first of its kind to draw a direct line between how companies operate internally and their financial performance. Companies were surve

Suzano Sells 12.7 Million Tonnes of Pulp for the First Time in Its History30.4.2026 01:22:00 EEST | Press release

Suzano(B3: SUZB3 | NYSE: SUZ), the world’s largest pulp producer, announces its results for the first quarter of 2026 (1Q26), achieving a new all‑time record in pulp sales. Over the 12‑month period from April 2025 to March 2026, the company sold 12.7 million tonnes of pulp, the highest volume ever recorded in its history. During the same period, Suzano also sold 1.7 million tonnes of paper across the packaging, printing and writing, specialty, and tissue segments. This unprecedented sales level mainly reflects the increase in production capacity following the start‑up of the Ribas do Rio Pardo pulp mill in the state of Mato Grosso do Sul, as well as Suzano’s strong operational efficiency across its production lines and supply chains, serving customers in more than 100 countries worldwide. In the first quarter of 2026, Suzano sold a total of 3.2 million tonnes, comprising 2.8 million tonnes of pulp and 378 thousand tonnes of paper. Net revenue amounted to BRL 11.0 billion, while adjuste

The Estée Lauder Companies Announces Minority Investment in Luxury Clinical Skin Care Brand 111SKIN29.4.2026 23:30:00 EEST | Press release

The Estée Lauder Companies Inc. (NYSE:EL) today announced a minority investment in 111SKIN, a luxury clinical skin care brand founded by renowned plastic and reconstructive surgeon Dr. Yannis Alexandrides. Terms of the investment were not disclosed. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429495879/en/ 111SKIN's Reparative Collection Founded in 2012, 111SKIN was originally developed by Dr. Alexandrides to accelerate his patients’ healing time following procedures. At the heart of the brand is its innovative NAC Y2™, a pioneering complex designed to support skin repair and maintain a healthy, radiant and resilient complexion. Building on the foundation of this clinical expertise, 111SKIN has developed a portfolio of more than 30 products, anchored by its Black Diamond and Reparative collections and priced from $50 to $1,000. “Skin care is entering a new phase, shaped by the convergence of procedures, longevity and b

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye